CSIMarket Company Name, Ticker, Industry, else..
 
Landos Biopharma Inc   (NASDAQ: LABP)
Other Ticker:  
 
 
Price: $22.9300 $0.13 0.583%
Day's High: $22.94 Week Perf: 2.05 %
Day's Low: $ 22.75 30 Day Perf: 3.38 %
Volume (M): 51 52 Wk High: $ 22.94
Volume (M$): $ 1,165 52 Wk Avg: $22.33
Open: $22.93 52 Wk Low: $21.61



 Market Capitalization (Millions $) 144
 Shares Outstanding (Millions) 6
 Employees 27
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) 20
 Cash Flow (TTM) (Millions $) 26
 Capital Exp. (TTM) (Millions $) 0

Landos Biopharma Inc
Landos Biopharma Inc is a biotechnology company that focuses on developing and commercializing novel therapeutics for autoimmune diseases. The company specializes in utilizing its proprietary platform, called LANCE, to discover and develop oral peptide-based therapies that target specific disease pathways. Landos Biopharma aims to improve the quality of life for patients suffering from autoimmune diseases by providing effective and convenient treatment options.


   Company Address: P.O. Box 11239 Blacksburg 24062 VA
   Company Phone Number: 218-2232   Stock Exchange / Ticker: NASDAQ LABP


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
ABBV   -1.18%    
AZN        1.66% 
JNJ        3.78% 
NVS        5.85% 
PFE        1.07% 
SNY   -1.19%    
• View Complete Report
   



Merger and Acquisition

Landos Biopharma's Groundbreaking NX-13 Provides Hope for Ulcerative Colitis Patients

Published Mon, Mar 25 2024 12:30 PM UTC


In the world of medical advancements, Landos Biopharma Inc. has emerged as a noteworthy player with its lead asset, NX-13 ? a first-in-class oral NLRX1 agonist currently in Phase 2 for the treatment of ulcerative colitis (UC). With this breakthrough in hand, Landos Biopharma is poised to revolutionize the management of this debilitating inflammatory bowel disease.
L...
Landos Biopharma Inc

Landos Biopharma Inc Demonstrates Encouraging Progress with Operating Loss Reduction of $-6.479 Million in Q1 2023

The first quarter of the reporting cycle for 2023 has seen a number of corporations in the Major Pharmaceutical Preparations sector declare their results, with notable changes in operating losses amongst the entities. Landos Biopharma Inc, for instance, reported an operating loss of $-6.479 million in the first quarter of 2023, which pales in comparison to the loss of $-12.403 million reported in the same period of 2021. This is a significant sign for the state of the company.
As a rising business in the sector, Landos Biopharma Inc continues to evolve its business model, with numerous stakeholders looking to the company's efficiency in running its operations. During the financial first quarter of 2023, executives successfully managed Landos Biopharma more effectively, reducing the company's deficit to $-6.034 million. This marks an improvement on the previous year, indicating that the company is moving in the right direction towards profitability.









Help

About us

Advertise
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2025 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com